{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:36:03Z","timestamp":1790030163845,"version":"4.0.1"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vancomycin remains the standard of care for treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in pediatrics largely because no alternative antibiotic is definitively superior. Long-standing historical precedent and S. aureus\u2019 notable lack of vancomycin resistance are clear benefits, but vancomycin\u2019s use remains plagued by nephrotoxicity and the need for therapeutic drug monitoring, with inadequate consensus on how best to dose or monitor vancomycin in pediatrics. Daptomycin, ceftaroline, and linezolid are all promising alternatives, with improved safety relative to vancomycin. However, inadequate and variable efficacy data limit confidence in their use. Despite this, we contend that it is time for clinicians to reconsider vancomycin\u2019s place in clinical use. In this review, we summarize the supporting data for using vancomycin versus these other anti-MRSA antibiotics, present a framework for antibiotic decision-making that considers patient-specific factors, and discuss approaches to antibiotic selection for various etiologies of MRSA bacteremia. This review aims to help pediatric clinicians choose among the various treatment options for MRSA bacteremia, acknowledging that the optimal antibiotic choice is sometimes uncertain.<\/jats:p>","DOI":"10.1093\/jpids\/piad032","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T13:45:38Z","timestamp":1683294338000},"page":"308-318","source":"Crossref","is-referenced-by-count":17,"title":["Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant <i>Staphylococcus aureus<\/i> Bacteremia"],"prefix":"10.1093","volume":"12","author":[{"given":"Andrew S","family":"Haynes","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Section of Pediatric Infectious Diseases, Children\u2019s Hospital Colorado , Aurora, Colorado , USA"},{"name":"University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Maples","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences College of Pharmacy , Little Rock, Arkansas , USA"},{"name":"Arkansas Children\u2019s, Quality and Safety Division , Little Rock, Arkansas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Pediatric Infectious Diseases, Children\u2019s Hospital Colorado , Aurora, Colorado , USA"},{"name":"University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"2023053114292580100_CIT0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/INF.0000000000000485","article-title":"Low mortality of Staphylococcus aureus bacteremia in Icelandic children: nationwide study on incidence and outcome","volume":"34","author":"Asgeirsson","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciab510","article-title":"Pediatric Staphylococcus aureus bacteremia: clinical spectrum and predictors of poor outcome","volume":"74","author":"Campbell","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1017\/ice.2014.91","article-title":"Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes","volume":"36","author":"Klieger","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023053114292580100_CIT0004","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapediatrics.2016.1477","article-title":"Epidemiology and mortality of Staphylococcus aureus bacteremia in Australian and New Zealand children","volume":"170","author":"McMullan","year":"2016","journal-title":"JAMA Pediatr"},{"key":"2023053114292580100_CIT0005","doi-asserted-by":"crossref","first-page":"e78396","DOI":"10.1371\/journal.pone.0078396","article-title":"Epidemiology of Staphylococcus aureus bacteraemia at a tertiary children\u2019s hospital in Cape Town, South Africa","volume":"8","author":"Naidoo","year":"2013","journal-title":"PLoS One"},{"key":"2023053114292580100_CIT0006","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0007","doi-asserted-by":"crossref","first-page":"e20200134","DOI":"10.1542\/peds.2020-0134","article-title":"Clinical management of Staphylococcus aureus bacteremia in neonates, children, and adolescents","volume":"146","author":"McMullan","year":"2020","journal-title":"Pediatrics"},{"key":"2023053114292580100_CIT0008","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","article-title":"Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first","volume":"72","author":"Lodise","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0009","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2023053114292580100_CIT0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jpids\/piaa078","article-title":"A moving target-vancomycin therapeutic monitoring","volume":"9","author":"Burns","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2023053114292580100_CIT0011","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/1060028015594190","article-title":"Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy","volume":"49","author":"Knoderer","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2023053114292580100_CIT0012","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jpids\/pit076","article-title":"Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?","volume":"3","author":"Knoderer","year":"2014","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2023053114292580100_CIT0013","doi-asserted-by":"crossref","first-page":"20681","DOI":"10.1038\/s41598-021-00214-9","article-title":"Vancomycin-induced nephrotoxicity in non-intensive care unit pediatric patients","volume":"11","author":"Kwak","year":"2021","journal-title":"Sci Rep"},{"key":"2023053114292580100_CIT0014","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","author":"McKamy","year":"2011","journal-title":"J Pediatr"},{"key":"2023053114292580100_CIT0015","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1111\/chd.12187","article-title":"Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients","volume":"10","author":"Moffett","year":"2015","journal-title":"Congenit Heart Dis"},{"key":"2023053114292580100_CIT0016","doi-asserted-by":"crossref","first-page":"e0202439","DOI":"10.1371\/journal.pone.0202439","article-title":"Vancomycin associated acute kidney injury in pediatric patients","volume":"13","author":"Moffett","year":"2018","journal-title":"PLoS One"},{"key":"2023053114292580100_CIT0017","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/INF.0000000000001882","article-title":"Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0018","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/jac\/dkab194","article-title":"Precision dosing of vancomycin: in defence of AUC-guided therapy in children","volume":"76","author":"Murphy","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023053114292580100_CIT0019","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053114292580100_CIT0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jpids\/piz036","article-title":"Intravenous vancomycin therapeutic drug monitoring in children: evaluation of a pharmacy-driven protocol and collaborative practice agreement","volume":"9","author":"Olson","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2023053114292580100_CIT0021","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ajhp\/zxab123","article-title":"Validity of 2020 vancomycin consensus recommendations and further guidance for practical application","volume":"78","author":"Rybak","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"2023053114292580100_CIT0022","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/ajhp\/zxab121","article-title":"Pragmatic application of AUC-based monitoring recommendations from the 2020 vancomycin consensus guidelines","volume":"78","author":"Schulz","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"2023053114292580100_CIT0023","doi-asserted-by":"crossref","first-page":"1346.e1","DOI":"10.1016\/j.cmi.2020.11.008","article-title":"Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023053114292580100_CIT0024","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/jac\/dkab048","article-title":"AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics","volume":"76","author":"Jorgensen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023053114292580100_CIT0025","doi-asserted-by":"crossref","first-page":"e20170183","DOI":"10.1542\/peds.2017-0183","article-title":"Epidemiology of methicillin-resistant staphylococcus aureus bacteremia in children","volume":"139","author":"Hamdy","year":"2017","journal-title":"Pediatrics"},{"key":"2023053114292580100_CIT0026","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1542\/peds.2011-0966","article-title":"Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants","volume":"129","author":"Shane","year":"2012","journal-title":"Pediatrics"},{"key":"2023053114292580100_CIT0027","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1440-1754.2002.00787.x","article-title":"Staphylococcus aureus bacteraemia in children: a 5-year retrospective review","volume":"38","author":"Suryati","year":"2002","journal-title":"J Paediatr Child Health"},{"key":"2023053114292580100_CIT0028","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00006454-200109000-00009","article-title":"Prospective study of 125 cases of Staphylococcus aureus bacteremia in children in New Zealand","volume":"20","author":"Hill","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0029","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2023053114292580100_CIT0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2023053114292580100_CIT0031","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1469-0691.2010.03265.x","article-title":"Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality","volume":"17","author":"Asgeirsson","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2023053114292580100_CIT0032","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023053114292580100_CIT0033","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0034","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2023053114292580100_CIT0035","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"2023053114292580100_CIT0036","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0037","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/cid\/ciab452","article-title":"Current paradigms of combination therapy in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: does it work, which combination, and for which patients?","volume":"73","author":"Rose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0038","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053114292580100_CIT0039","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2019.08.011","article-title":"Daptomycin-containing regimens for treatment of Gram-positive endocarditis","volume":"54","author":"Russo","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023053114292580100_CIT0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2023053114292580100_CIT0041","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053114292580100_CIT0042","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0043","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1 mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0044","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/antibiotics10081014","article-title":"Daptomycin versus Vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis","volume":"10","author":"Maraolo","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023053114292580100_CIT0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC &gt;1 mg\/L: a multicenter evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin Ther"},{"key":"2023053114292580100_CIT0046","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/INF.0000000000002790","article-title":"Daptomycin for pediatric gram-positive acute hematogenous osteomyelitis","volume":"39","author":"Bradley","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0047","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcph.1576","article-title":"Pharmacokinetic\/pharmacodynamic analysis of daptomycin against Staphylococcus aureus and Enterococcus faecium in pediatric patients by Monte Carlo simulation","volume":"60","author":"Wei","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2023053114292580100_CIT0048","doi-asserted-by":"crossref","first-page":"ofab418","DOI":"10.1093\/ofid\/ofab418","article-title":"Vancomycin or daptomycin for outpatient parenteral antibiotic therapy: does it make a difference in patient satisfaction?","volume":"8","author":"Wu","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023053114292580100_CIT0049","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diagmicrobio.2018.09.004","article-title":"Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli","volume":"93","author":"Crass","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023053114292580100_CIT0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/JCM.44.2.595-597.2006","article-title":"Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"44","author":"Marty","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2023053114292580100_CIT0051","doi-asserted-by":"crossref","first-page":"ofac137","DOI":"10.1093\/ofid\/ofac137","article-title":"Approaching 65 years: is it time to consider retirement of vancomycin for treating methicillin-resistant staphylococcus aureus endovascular infections?","volume":"9","author":"Rose","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023053114292580100_CIT0052","doi-asserted-by":"crossref","first-page":"e01293-17","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053114292580100_CIT0053","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an Academic Medical Center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2023053114292580100_CIT0054","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0055","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2023053114292580100_CIT0056","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2023053114292580100_CIT0057","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jgar.2021.10.027","article-title":"Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials","volume":"28","author":"Dryden","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2023053114292580100_CIT0058","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023053114292580100_CIT0059","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"2023053114292580100_CIT0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2023053114292580100_CIT0061","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1097\/PCC.0000000000001497","article-title":"Ceftaroline for suspected or confirmed invasive methicillin-resistant staphylococcus aureus: a pharmacokinetic case series","volume":"19","author":"Cies","year":"2018","journal-title":"Pediatr Crit Care Med"},{"key":"2023053114292580100_CIT0062","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053114292580100_CIT0063","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023053114292580100_CIT0064","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12879-019-3791-z","article-title":"Use of ceftaroline fosamil in osteomyelitis: CAPTURE study experience","volume":"19","author":"Johnson","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023053114292580100_CIT0065","doi-asserted-by":"crossref","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant staphylococcus aureus bloodstream infection","volume":"9","author":"Zasowski","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023053114292580100_CIT0066","first-page":"342","article-title":"Pharmacokinetics of ceftaroline in a preterm infant with methicillin-resistant staphylococcus aureus pneumonia","volume":"7","author":"Salerno","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2023053114292580100_CIT0067","first-page":"476","article-title":"Ceftaroline fosamil use in 2 pediatric patients with invasive methicillin-resistant Staphylococcus aureus infections","volume":"20","author":"Williams","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2023053114292580100_CIT0068","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0069","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000001160","article-title":"A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia","volume":"35","author":"Blumer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0070","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0071","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023053114292580100_CIT0072","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cStatic vs Cidal\u201d: a systemic literature review","volume":"66","author":"Wald-Dickler","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0073","doi-asserted-by":"crossref","first-page":"106329","DOI":"10.1016\/j.ijantimicag.2021.106329","article-title":"Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"57","author":"Yeager","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2023053114292580100_CIT0074","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","volume":"69","author":"Willekens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0076","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2023053114292580100_CIT0077","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0078","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/j.ijid.2009.10.002","article-title":"Use of linezolid in pediatrics: a critical review","volume":"14","author":"Dotis","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2023053114292580100_CIT0079","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2023053114292580100_CIT0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0081","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0082","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0083","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40261-021-01077-8","article-title":"Exploratory cost-effectiveness analysis for treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: is linezolid or daptomycin favored over vancomycin?","volume":"41","author":"Vu","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2023053114292580100_CIT0084","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023053114292580100_CIT0085","doi-asserted-by":"crossref","first-page":"e02483-18","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053114292580100_CIT0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz746","article-title":"Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","volume":"71","author":"Jorgensen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0087","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2023053114292580100_CIT0088","doi-asserted-by":"crossref","first-page":"dlac014","DOI":"10.1093\/jacamr\/dlac014","article-title":"Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)\u2014an open-labelled pilot randomized controlled trial","volume":"4","author":"Campbell","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023053114292580100_CIT0089","doi-asserted-by":"crossref","first-page":"e0230383","DOI":"10.1371\/journal.pone.0230383","article-title":"Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: a meta-analysis","volume":"15","author":"Ma","year":"2020","journal-title":"PLoS One"},{"key":"2023053114292580100_CIT0090","first-page":"490","article-title":"Ceftaroline plus daptomycin for refractory methicillin-resistant Staphylococcus aureus bacteremia in a child","volume":"23","author":"Hall","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2023053114292580100_CIT0091","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0092","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/cid\/ciy495","article-title":"Vancomycin monotherapy may be insufficient to treat methicillin-resistant staphylococcus aureus coinfection in children with influenza-related critical illness","volume":"68","author":"Randolph","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023053114292580100_CIT0093","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2023053114292580100_CIT0094","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIR.0000000000000298","article-title":"Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association","volume":"132","author":"Baltimore","year":"2015","journal-title":"Circulation"},{"key":"2023053114292580100_CIT0095","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2023053114292580100_CIT0096","year":"2020"},{"key":"2023053114292580100_CIT0097","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jpids\/piab027","article-title":"Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics","volume":"10","author":"Woods","year":"2021","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2023053114292580100_CIT0098","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2023053114292580100_CIT0099","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s15010-011-0240-3","article-title":"Serum levels of daptomycin in pediatric patients","volume":"40","author":"Antachopoulos","year":"2012","journal-title":"Infection"},{"key":"2023053114292580100_CIT0100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/INF.0b013e31825d2fa2","article-title":"Pharmacokinetics and tolerability of single-dose daptomycin in young infants","volume":"31","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/INF.0000000000002607","article-title":"Phase 2 study of the safety, pharmacokinetics and efficacy of ceftaroline fosamil in neonates and very young infants with late-onset sepsis","volume":"39","author":"Bradley","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0102","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/INF.0000000000002067","article-title":"Population pharmacokinetics of intravenous linezolid in premature infants","volume":"38","author":"Thibault","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0103","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/antibiotics10020168","article-title":"Safety and efficacy of daptomycin in neonates with coagulase-negative staphylococci: case series analysis","volume":"10","author":"Mohzari","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023053114292580100_CIT0104","first-page":"68","article-title":"Methicillin-resistant Staphylococcus aureus endovascular infection in a neonate: prolonged, safe, and effective use of daptomycin and enoxaparin","volume":"25","author":"Chan","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2023053114292580100_CIT0105","first-page":"61","article-title":"Successful use of daptomycin in a preterm neonate with persistent methicillin-resistant Staphylococcus epidermidis bacteremia","volume":"20","author":"Gawronski","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2023053114292580100_CIT0106","first-page":"457","article-title":"Daptomycin for treatment of S. epidermidis endocarditis in an extremely preterm neonate-outcome and perspectives","volume":"9","author":"Minotti","year":"2022","journal-title":"Children (Basel)"},{"key":"2023053114292580100_CIT0107","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.pedneo.2021.03.007","article-title":"Successful daptomycin therapy for a premature neonate with left-sided infective endocarditis caused by Staphylococcus epidermidis","volume":"62","author":"Shigeta","year":"2021","journal-title":"Pediatr Neonatol"},{"key":"2023053114292580100_CIT0108","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13052-020-00854-z","article-title":"Staphylococcal meningitis therapy with linezolid in a young infant: efficacy, CSF levels and side effects","volume":"46","author":"Auriti","year":"2020","journal-title":"Ital J Pediatr"},{"key":"2023053114292580100_CIT0109","first-page":"415","article-title":"Enteral linezolid as an effective option to treat an extremely preterm infant with bacillus cereus sepsis","volume":"9","author":"Minotti","year":"2022","journal-title":"Children (Basel)"},{"key":"2023053114292580100_CIT0110","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00431-013-1978-7","article-title":"Treatment with linezolid in a neonate with meningitis caused by methicillin-resistant Staphylococcus epidermidis","volume":"172","author":"Watanabe","year":"2013","journal-title":"Eur J Pediatr"},{"key":"2023053114292580100_CIT0111","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/01.inf.0000086955.93702.c7","article-title":"Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates","volume":"22","author":"Deville","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2023053114292580100_CIT0112","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jiac.2018.04.006","article-title":"Comparative study on safety of linezolid and vancomycin in the treatment of infants and neonates for Gram-positive bacterial infections","volume":"24","author":"Shibata","year":"2018","journal-title":"J Infect Chemother"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piad032\/50212275\/piad032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/12\/5\/308\/50494977\/piad032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/12\/5\/308\/50494977\/piad032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T14:35:30Z","timestamp":1685543730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/12\/5\/308\/7152990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":112,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2023,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piad032","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,5,1]]}}}